Patients with acute coronary syndrome who were treated with the experimental drug varespladib were more likely to experience additional cardiovascular events — including sudden death, heart attack and stroke — than those treated with placebo, according to research from the Cleveland Clinic Coordinating Center for Clinical Research.
Fuente : http://www.eurekalert.org/pub_releases/2013-11/cc-…
Hacer un comentario